Hottest Stock Pick for 2021
This could be the most underrated stock available. Watch it closely.

NASDAQ:EXAS - Exact Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $151.06
  • Forecasted Upside: 57.32 %
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 12 Buy Ratings
  • 1 Strong Buy Ratings
$96.02
▼ -2.2 (-2.24%)

This chart shows the closing price for EXAS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exact Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXAS

Analyst Price Target is $151.06
▲ +57.32% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $151.06, with a high forecast of $180.00 and a low forecast of $120.00. The average price target represents a 57.32% upside from the last price of $96.02.

This chart shows the closing price for EXAS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
Hottest Stock Pick for 2021
This could be the most underrated stock available. Watch it closely.

Current Consensus is Buy

The current consensus among 16 contributing investment analysts is to buy stock in Exact Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/30/2021
  • 1 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/28/2021
  • 1 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/27/2021
  • 1 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/26/2021

Latest Recommendations

  • 1 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/29/2021Stifel NicolausLower Price TargetBuy$165.00 ➝ $145.00High
7/29/2021BTIG ResearchLower Price TargetBuy$155.00 ➝ $145.00High
7/29/2021Canaccord GenuityLower Price TargetBuy$185.00 ➝ $160.00High
7/29/2021OppenheimerLower Price TargetOutperform$161.00 ➝ $155.00High
7/29/2021Robert W. BairdLower Price TargetOutperform$157.00 ➝ $127.00High
7/14/2021SVB LeerinkLower Price TargetOutperform$170.00 ➝ $160.00High
6/21/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$115.00 ➝ $120.00Low
6/15/2021Raymond JamesInitiated CoverageStrong-Buy$160.00Medium
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
5/25/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$115.00Low
5/12/2021TruistLower Price Target$226.00 ➝ $168.00Medium
5/12/2021Truist SecuritiesLower Price TargetBuy$226.00 ➝ $168.00Medium
5/5/2021Craig HallumLower Price TargetBuy$161.00 ➝ $144.00High
5/5/2021BTIG ResearchLower Price TargetBuy$175.00 ➝ $155.00High
5/5/2021SVB LeerinkLower Price TargetOutperform$180.00 ➝ $170.00High
2/18/2021Robert W. BairdLower Price TargetOutperform$169.00 ➝ $163.00Low
2/17/2021Stifel NicolausBoost Price TargetBuy$150.00 ➝ $165.00Low
2/17/2021SVB LeerinkBoost Price TargetMarket Perform ➝ Outperform$170.00 ➝ $180.00Low
2/17/2021CowenBoost Price TargetOutperform$154.00 ➝ $180.00Low
1/27/2021TruistInitiated CoverageBuy$226.00 ➝ $226.00Medium
1/21/2021SVB LeerinkBoost Price TargetOutperform$160.00 ➝ $170.00Medium
1/12/2021Canaccord GenuityBoost Price TargetBuy$160.00 ➝ $165.00Low
10/29/2020UBS GroupDowngradeBuy ➝ Neutral$125.00 ➝ $140.00High
10/28/2020Canaccord GenuityBoost Price TargetBuy$120.00 ➝ $145.00Low
10/28/2020OppenheimerBoost Price Target$115.00 ➝ $150.00Low
10/28/2020BTIG ResearchBoost Price Target$140.00 ➝ $155.00Low
10/28/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$120.00 ➝ $140.00Low
10/28/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$135.00 ➝ $150.00Low
10/28/2020SVB LeerinkBoost Price TargetOutperform$115.00 ➝ $160.00Low
10/28/2020BenchmarkBoost Price TargetBuy$110.00 ➝ $145.00Low
9/25/2020Canaccord GenuityBoost Price TargetBuy$115.00 ➝ $120.00Low
7/31/2020SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $115.00High
7/31/2020BenchmarkBoost Price TargetBuy$90.00 ➝ $110.00Low
7/31/2020CitigroupBoost Price TargetBuy$110.00 ➝ $120.00Low
7/8/2020OppenheimerReiterated RatingBuyHigh
6/25/2020CitigroupBoost Price TargetBuy$100.00 ➝ $110.00Medium
5/7/2020Robert W. BairdBoost Price TargetOutperform$90.00 ➝ $92.00Low
5/7/2020Bank of AmericaBoost Price TargetBuy$88.00 ➝ $94.00Low
5/7/2020Craig HallumLower Price TargetIn-Line ➝ Buy$99.00 ➝ $92.00Low
5/7/2020Canaccord GenuityLower Price TargetBuy$120.00 ➝ $110.00High
5/7/2020SVB LeerinkLower Price TargetOutperform$100.00 ➝ $90.00High
4/28/2020UBS GroupLower Price TargetBuy$135.00 ➝ $115.00High
4/22/2020CitigroupLower Price TargetBuy$120.00 ➝ $100.00Medium
4/22/2020Robert W. BairdLower Price TargetOutperform$100.00 ➝ $90.00High
4/21/2020OppenheimerReiterated RatingBuy$115.00Low
4/17/2020Craig HallumLower Price TargetBuy$127.00 ➝ $99.00High
4/2/2020Stifel NicolausLower Price TargetBuy$110.00 ➝ $90.00Low
4/2/2020Evercore ISIInitiated CoverageOutperform$70.00High
2/14/2020Stifel NicolausReiterated RatingBuy$110.00N/A
2/12/2020Robert W. BairdReiterated RatingBuyLow
2/12/2020Canaccord GenuityReiterated RatingBuy$120.00High
2/6/2020Canaccord GenuityReiterated RatingBuy$120.00Low
1/10/2020BTIG ResearchInitiated CoverageBuy$127.00High
1/6/2020CitigroupInitiated CoverageBuy$120.00Low
12/13/2019Dougherty & CoInitiated CoverageBuy$120.00Low
11/14/2019Stifel NicolausInitiated CoverageBuy$110.00High
10/31/2019Bank of AmericaReiterated RatingBuy$135.00Medium
10/30/2019SVB LeerinkLower Price TargetOutperform$133.00 ➝ $105.00Medium
10/30/2019Canaccord GenuityLower Price TargetBuy$135.00 ➝ $120.00High
10/30/2019Jefferies Financial GroupLower Price TargetBuy$138.00 ➝ $120.00High
10/17/2019Bank of AmericaBoost Price TargetBuy$130.00 ➝ $135.00Low
9/26/2019OppenheimerInitiated CoverageOutperform$130.00Medium
9/24/2019SVB LeerinkReiterated RatingBuyHigh
9/23/2019BenchmarkUpgradeHold ➝ Buy$130.00High
9/10/2019William BlairReiterated RatingBuyLow
9/10/2019Canaccord GenuityReiterated RatingBuy$135.00Low
8/1/2019UBS GroupBoost Price TargetBuy$120.00 ➝ $143.00Low
7/30/2019Craig HallumBoost Price TargetBuy$115.00 ➝ $127.00Medium
7/29/2019CowenBoost Price TargetOutperform$125.00 ➝ $135.00Low
7/17/2019Canaccord GenuityReiterated RatingBuy$118.00 ➝ $125.00Low
5/1/2019Jefferies Financial GroupBoost Price TargetBuy$100.00 ➝ $115.00Low
5/1/2019UBS GroupBoost Price TargetBuy ➝ Buy$115.00 ➝ $120.00Low
5/1/2019Craig HallumReiterated RatingBuy$95.00 ➝ $115.00Low
5/1/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$100.00 ➝ $110.00Medium
5/1/2019BTIG ResearchBoost Price TargetBuy$130.00Low
4/16/2019UBS GroupBoost Price TargetBuy ➝ Buy$109.00 ➝ $115.00Low
2/26/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$85.00 ➝ $120.00Medium
2/22/2019UBS GroupSet Price TargetBuy$109.00Low
2/22/2019Craig HallumSet Price TargetIn-Line ➝ Buy$77.00 ➝ $95.00High
2/22/2019BTIG ResearchBoost Price TargetBuy ➝ Positive$110.00High
2/21/2019Robert W. BairdBoost Price TargetOutperform$90.00 ➝ $102.00High
1/28/2019UBS GroupBoost Price TargetBuy$100.00 ➝ $109.00Medium
1/14/2019Canaccord GenuityBoost Price TargetBuy$87.00 ➝ $95.00High
1/7/2019William BlairReiterated RatingOutperformHigh
11/29/2018UBS GroupSet Price TargetBuy$100.00Low
10/31/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$74.00 ➝ $84.00Low
10/30/2018UBS GroupSet Price TargetBuy$100.00High
10/9/2018UBS GroupInitiated CoverageBuy ➝ Buy$100.00Low
9/12/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$72.00 ➝ $87.00Low
9/11/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$74.00 ➝ $85.00Low
9/6/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$68.00 ➝ $92.00Medium
9/5/2018CowenBoost Price TargetOutperform$65.00 ➝ $100.00High
9/5/2018BenchmarkReiterated RatingHold ➝ HoldHigh
8/30/2018The Goldman Sachs GroupBoost Price TargetNeutral$75.00Low
8/23/2018Craig HallumBoost Price TargetBuy$54.00 ➝ $74.00Medium
8/23/2018Jefferies Financial GroupReiterated RatingBuy$74.00High
8/23/2018SVB LeerinkReiterated RatingOutperform$90.00High
8/23/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $74.00High
8/22/2018BTIG ResearchBoost Price TargetBuy$95.00High
8/13/2018Canaccord GenuityReiterated RatingBuy$62.00 ➝ $65.00Low
8/3/2018Canaccord GenuityReiterated RatingBuy$62.00Medium
8/2/2018Jefferies Financial GroupLower Price TargetBuy ➝ Buy$60.00 ➝ $57.00High
8/2/2018Bank of AmericaLower Price TargetBuy ➝ Buy$75.00 ➝ $68.00High
8/2/2018Craig HallumLower Price TargetBuy$60.00 ➝ $54.00High
7/23/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$67.00 ➝ $75.00Medium
7/18/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$67.00 ➝ $76.00Low
7/9/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $70.00Low
6/18/2018CowenBoost Price TargetOutperform$65.00 ➝ $85.00Low
6/15/2018Canaccord GenuityBoost Price TargetBuy$70.00 ➝ $75.00Medium
6/6/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$68.00 ➝ $70.00Low
6/5/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $66.00Medium
6/5/2018BTIG ResearchReiterated RatingBuyMedium
5/31/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$60.00 ➝ $68.00Medium
5/30/2018BTIG ResearchBoost Price TargetPositive ➝ Buy$60.00 ➝ $70.00High
4/29/2018BTIG ResearchReiterated RatingBuy$60.00High
4/27/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$55.00 ➝ $60.00High
4/3/2018BTIG ResearchUpgradeNeutral ➝ BuyLow
3/29/2018William BlairReiterated RatingBuyN/A
3/28/2018SVB LeerinkSet Price TargetBuy$67.00High
2/27/2018Robert W. BairdUpgradeNeutral ➝ Outperform$42.56 ➝ $56.00Medium
2/23/2018SVB LeerinkSet Price TargetBuy$67.00High
2/23/2018BenchmarkDowngradeBuy ➝ HoldHigh
2/9/2018SVB LeerinkSet Price TargetBuy$67.00Medium
1/29/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$17.77 ➝ $51.00Low
1/17/2018BenchmarkSet Price TargetBuy$65.00Medium
1/10/2018William BlairReiterated RatingBuyHigh
1/8/2018Bank of AmericaSet Price TargetBuy$67.00High
1/2/2018William BlairReiterated RatingBuyLow
11/29/2017Bank of AmericaBoost Price TargetBuy$58.00 ➝ $67.00Low
11/13/2017SVB LeerinkReiterated RatingOutperform$63.00 ➝ $67.00N/A
11/13/2017Robert W. BairdDowngradeOutperform ➝ Neutral$56.00N/A
11/1/2017BTIG ResearchDowngradeBuy ➝ NeutralN/A
10/31/2017Bank of AmericaBoost Price TargetBuy$56.00 ➝ $58.00N/A
10/31/2017Canaccord GenuityUpgradeBuy$60.00N/A
10/31/2017Robert W. BairdBoost Price TargetOutperform$49.00 ➝ $56.00N/A
10/31/2017Craig HallumBoost Price TargetBuy$46.00 ➝ $61.00N/A
10/31/2017BenchmarkReiterated RatingBuy ➝ Buy$50.00 ➝ $60.00N/A
10/31/2017SVB LeerinkReiterated RatingOutperform$50.00 ➝ $63.00N/A
10/31/2017Jefferies Financial GroupBoost Price TargetBuy$60.00N/A
10/19/2017Bank of AmericaSet Price TargetBuy$40.00 ➝ $56.00N/A
10/6/2017Robert W. BairdReiterated RatingBuy$49.00N/A
10/3/2017Canaccord GenuityReiterated RatingBuy ➝ Buy$45.00 ➝ $60.00High
9/21/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$45.00 ➝ $50.00High
9/7/2017Canaccord GenuityReiterated RatingBuy$45.00Low
8/24/2017SVB LeerinkSet Price TargetBuy$45.00Medium
7/26/2017Canaccord GenuityReiterated RatingBuy ➝ Buy$42.00 ➝ $45.00High
7/26/2017Bank of AmericaReiterated RatingBuyHigh
7/26/2017Roth CapitalBoost Price TargetBuy$40.00 ➝ $46.00High
7/26/2017Craig HallumReiterated RatingBuy$41.00 ➝ $46.00High
7/26/2017Lake Street CapitalBoost Price TargetHold ➝ Hold$30.00 ➝ $41.00Medium
7/20/2017Canaccord GenuityReiterated RatingBuy$38.00 ➝ $42.00Medium
7/17/2017BTIG ResearchReiterated RatingBuy$35.00 ➝ $45.00Low
7/7/2017BenchmarkSet Price TargetBuy$50.00Low
7/7/2017Craig HallumBoost Price Target$35.00 ➝ $41.00High
6/12/2017Bank of AmericaReiterated RatingBuy$34.00 ➝ $38.00Low
6/9/2017Canaccord GenuityLower Price TargetBuy$40.00 ➝ $38.00Low
6/7/2017StephensSet Price TargetHold$28.00Medium
6/1/2017Roth CapitalReiterated RatingBuy$33.00 ➝ $40.00Low
6/1/2017Robert W. BairdReiterated RatingOutperform$40.00Low
6/1/2017Jefferies Financial GroupSet Price TargetBuy$35.00Medium
5/31/2017Canaccord GenuityBoost Price TargetBuy ➝ Buy$38.00 ➝ $40.00High
5/31/2017CowenReiterated RatingOutperform$45.00High
5/31/2017BenchmarkBoost Price TargetBuy ➝ Buy$34.00 ➝ $50.00High
5/16/2017Jefferies Financial GroupReiterated RatingBuy$35.00Low
5/15/2017CowenBoost Price TargetOutperform$40.00 ➝ $45.00N/A
5/5/2017CowenBoost Price TargetOutperform$40.00 ➝ $45.00Low
5/1/2017The Goldman Sachs GroupSet Price TargetNeutral$21.00 ➝ $33.00Medium
4/28/2017SVB LeerinkSet Price TargetBuy$38.00Medium
4/27/2017CowenBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $40.00Low
4/26/2017Jefferies Financial GroupReiterated RatingBuy$25.00High
4/24/2017Canaccord GenuityReiterated RatingBuy$27.00Low
4/17/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$30.00Low
4/4/2017CowenReiterated RatingOutperform$30.00Low
3/29/2017Bank of AmericaReiterated RatingBuyHigh
3/27/2017Craig HallumSet Price TargetBuy$28.00High
3/27/2017CowenInitiated CoverageOutperform$30.00High
2/22/2017Canaccord GenuityReiterated RatingBuy$27.00 ➝ $24.00N/A
2/22/2017Roth CapitalUpgradeNeutral ➝ Buy$15.00 ➝ $26.00N/A
2/21/2017BenchmarkUpgradeHold ➝ Buy$17.00 ➝ $27.00N/A
1/31/2017Craig HallumSet Price TargetBuy$26.00N/A
1/23/2017Canaccord GenuitySet Price TargetBuy$24.00N/A
1/9/2017Canaccord GenuitySet Price TargetBuy$24.00N/A
1/8/2017BTIG ResearchReiterated RatingBuy$22.00N/A
12/20/2016Robert W. BairdSet Price TargetBuy$22.00N/A
12/13/2016Canaccord GenuitySet Price TargetBuy$24.00N/A
11/9/2016Canaccord GenuitySet Price TargetBuy$24.00N/A
11/1/2016Lake Street CapitalLower Price TargetHold$15.00 ➝ $8.00N/A
10/28/2016Canaccord GenuityReiterated RatingBuy$24.00N/A
10/26/2016BenchmarkBoost Price TargetHold$14.00 ➝ $17.00N/A
10/4/2016Jefferies Financial GroupBoost Price TargetBuy$20.00 ➝ $23.00N/A
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/29/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
8/28/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Exact Sciences logo
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
Read More

Today's Range

Now: $96.02
Low: $95.50
High: $98.06

50 Day Range

MA: $104.01
Low: $90.24
High: $118.03

52 Week Range

Now: $96.02
Low: $89.65
High: $159.54

Volume

1,381,100 shs

Average Volume

1,540,439 shs

Market Capitalization

$16.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?

The following Wall Street analysts have issued reports on Exact Sciences in the last year: Benchmark Co., BTIG Research, Canaccord Genuity, Cowen Inc, Craig Hallum, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist, Truist Securities, UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for EXAS.

What is the current price target for Exact Sciences?

16 Wall Street analysts have set twelve-month price targets for Exact Sciences in the last year. Their average twelve-month price target is $151.06, suggesting a possible upside of 57.3%. Cowen Inc has the highest price target set, predicting EXAS will reach $180.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $120.00 for Exact Sciences in the next year.
View the latest price targets for EXAS.

What is the current consensus analyst rating for Exact Sciences?

Exact Sciences currently has 3 hold ratings, 12 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXAS will outperform the market and that investors should add to their positions of Exact Sciences.
View the latest ratings for EXAS.

How do I contact Exact Sciences' investor relations team?

Exact Sciences' physical mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company's listed phone number is (608) 284-5700 and its investor relations email address is [email protected] The official website for Exact Sciences is www.exactsciences.com.

Hottest Stock Pick for 2021
This could be the most underrated stock available. Watch it closely.